Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
As of April, 2011 Bayer transferred this record to Genzyme. Genzyme is now the sponsor of this trial. NOTE: This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must have confirmed B-CLL.
Patients must have received at least one prior therapy and must require treatment for active disease
You may not be if
Treatment with any anti-cancer agents (chemotherapies, monoclonal antibodies, etc) within 4 weeks of start of study.
History of significant allergic reaction to antibody therapies that required discontinuation of antibody therapy
History of human immunodeficiency virus (HIV) positivity.
Active infection requiring treatment
Pregnancy or lactation
Other severe, concurrent diseases or mental disorders
Central nervous system involvement of chronic lymphocytic leukemia (CLL)
Clareo Health | Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
